Showing results (151-160 of 202) with videos related to

Sort By:
Pageof 21
Allergy|October 9, 2016
European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessmentM A Calderón, C Vidal, P Rodríguez Del Río, et al.
Rhinology|July 20, 2019
ARIA masterclass 2018: From guidelines to real-life implementationP W Hellings, S F Seys, G Marien, et al.
Allergy|April 28, 2015
Clinical contraindications to allergen immunotherapy: an EAACI position paperC Pitsios, P Demoly, M B Bilò, et al.
Gene Therapy|April 20, 2016
Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapiesK Roellecke, E L Virts, R Einholz, et al.
HNO|December 29, 2025
[Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 2: Hypersensitivity reactions of type V (epithelial barrier defects)]L Klimek, S Becker, B Haxel, et al.
HNO|April 8, 2025
[Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 1: Hypersensitivity reactions of type IVa-c as a correlate to T1, T2, and T3 endotypes]L Klimek, S Becker, B Haxel, et al.
HNO|February 3, 2026
[Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 3: Hypersensitivity reactions of type VI]L Klimek, S Becker, B Haxel, et al.
The World Allergy Organization Journal|November 12, 2019
Strong dose response after immunotherapy with PQ grass using conjunctival provocation testingS Zielen, P Kuna, W Aberer, et al.
Allergy|November 23, 2016
Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis - an EAACI position paperO Pfaar, K Bastl, U Berger, et al.
Allergy|April 26, 2014
Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position PaperO Pfaar, P Demoly, R Gerth van Wijk, et al.
Pageof 21